PUBLIC HEALTH MODEL SYSTEM--BLOOD CHOLESTEROL SCREENING

马萨诸塞州公共卫生部建议实施一项 胆固醇筛查、教育和 转诊。 在四个不同种族，民族， 和社会经济群体，它将教育医生， 治疗中度和高度糖尿病患者的重要性和方法 血清胆固醇，并建立一个转诊网络的医生愿意 接受这样的病人。 在进行社区分析以确定最合适的地点之后， 进行筛选和最有效的招募手段 为了筛选志愿者，该部门将使用一个受过专门训练的小组， 在每个国家开展筛查、教育和转诊计划， 社区 大约11，000人将使用 便携式Reflotron分析仪。 将抽取静脉穿刺样本， 分析十分之一的筛选，以验证可靠性 Reflotron的决定。 筛查者将接受有关血清的教育和咨询 胆固醇和饮食的健康专业人士或训练有素的外行 人. 将与其中一半的人进行额外的接触 医生在两周内，以看看这是否会增加率 成功的转介。 将对所有个人进行跟踪 转介给医生以确定转介成功率， 开了什么处方 对于那些被提及的子样本， 将在六个月后开展后续活动，以确定变化 饮食中的脂肪消耗以及是否服用任何药物。 将对该子样本重复采集Reflotron血液样本，以观察 血清胆固醇水平自初次筛查以来是否发生变化。

The Massachusetts Department of Public Health proposes to implement a public health model system for cholesterol screening, education, and referral. Working in four communities with a diversity of racial, ethnic, and socioeconomic populations, it will educate physicians as to the importance and means of treating patients with moderate and high levels of serum cholesterol and establish a referral network of physicians willing to accept such patients. After conducting community analyses to establish the most appropriate sites for conducting screenings and the most effective means of recruiting volunteers to be screened, the Department will use a specially trained team to conduct its screening, education, and referral programs in each community. Approximately 11,000 individuals will be screened using a portable Reflotron analyzer. Venipuncture samples will be drawn and analyzed for one-tenth of those screened in order to verify the reliability of the Reflotron determinations. Those screened will receive education and counseling about serum cholesterol and diet by either a health professional or a trained lay person. Additional contact will be made with one-half of those referred to physicians within two weeks in order to see whether this increases the rate of successful referrals. Follow-up will be conducted on all individuals referred to physicians to determine the rate of successful referrals and what treatments have been prescribed. For a subsample of those referred, follow-up activities will be conducted at six months to ascertain changes in dietary fat consumption and whether any medications are being taken. Repeat Reflotron blood samples will be taken on this subsample to see whether serum cholesterol levels have changed since the initial screening.